Global Myasthenia Gravis Treatment Market Size & Outlook
Global myasthenia gravis treatment market, 2022-2045 (US$M)
Related Markets
Global myasthenia gravis treatment market highlights
- The global myasthenia gravis treatment market generated a revenue of USD 3,163.7 million in 2024 and is expected to reach USD 6,637.0 million by 2045.
- The market is expected to grow at a CAGR (2025 - 2045) of 2.7% by 2045.
- In terms of segment, fcrn inhibitors accounted for a revenue of USD 2,458.4 million in 2024.
- Complement Inhibitors is the most lucrative drug class segment registering the fastest growth during the forecast period.
- In terms of region, North America was the largest revenue generating market in 2024.
- Country-wise, India is expected to register the highest CAGR from 2025 to 2045.
Global data book summary
| Market revenue in 2024 | USD 3,163.7 million |
| Market revenue in 2045 | USD 6,637.0 million |
| Growth rate | 2.7% (CAGR from 2025 to 2045) |
| Largest segment | Fcrn inhibitors |
| Fastest growing segment | Complement Inhibitors |
| Historical data covered | 2022 - 2023 |
| Base year for estimation | 2024 |
| Forecast period covered | 2025 - 2045 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Complement Inhibitors, FcRn Inhibitors, Cholinesterase Inhibitors |
Other key industry trends
- In terms of revenue, the North America accounted for 71.4% of the global myasthenia gravis treatment market in 2024.
- By country, the U.S. is projected to lead the global market in terms of revenue in 2045.
- By country, India is the fastest growing regional market and is projected to reach USD 332.6 million by 2045.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Myasthenia Gravis Treatment Market Scope
Myasthenia Gravis Treatment Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Avadel Pharmaceuticals PLC | View profile | 154 | 10 Earlsfort Terrace, Dublin 2, Dublin, Ireland, D02 T380 | https://www.avadel.com |
| GlaxoSmithKline | View profile | 10001+ | London, England, United Kingdom, Europe | http://www.gsk.com |
| Bausch Health Companies Inc | View profile | 20270 | 2150 Saint Elzear Boulvard West, Laval, QC, Canada, H7L 4A8 | https://www.bauschhealth.com |
| Takeda Pharmaceutical Co Ltd | View profile | 49095 | 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, Japan, 103-8668 | https://www.takeda.com |
| AstraZeneca PLC | View profile | 89900 | 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom, CB2 0AA | https://www.astrazeneca.com |
| Grifols SA Ordinary Shares - Class A | View profile | 23737 | Avinguda de la Generalitat, 152, Parc de Negocis Can Sant Joan, Sant Cugat del Valles, Barcelona, Spain, 08174 | https://www.grifols.com |
| Roche Holding AG | View profile | 103605 | Grenzacherstrasse 124, Basel, Switzerland, 4070 | https://www.roche.com |
| Pfizer Inc | View profile | 88000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | https://www.pfizer.com |
| AbbVie Inc | View profile | 50000 | 1 North Waukegan Road, North Chicago, IL, United States, 60064-6400 | http://www.abbvieinvestor.com |
| Novartis AG ADR | View profile | 76057 | Lichtstrasse 35, Basel, Switzerland, 4056 | https://www.novartis.com |
Global myasthenia gravis treatment market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to myasthenia gravis treatment market will help companies and investors design strategic landscapes.
Fcrn inhibitors was the largest segment with a revenue share of 77.71% in 2024. Horizon Databook has segmented the Global myasthenia gravis treatment market based on complement inhibitors, fcrn inhibitors, cholinesterase inhibitors covering the revenue growth of each sub-segment from 2022 to 2045.
- Global Myasthenia Gravis Treatment Drug Class Outlook (Revenue, USD Million, 2022-2045)
- Complement Inhibitors
- Soliris (Eculizumab)
- Ultomiris (Ravulizumab)
- Zilbrysq (Zilucoplan)
- Veopoz (Pozelimab)
- Gefurulimab
- FcRn Inhibitors
- Vyvgart (Efgartigimod)
- Rozanolixizumab
- Batoclimab
- Other FcRn Inhibitors
- Cholinesterase Inhibitors
- Pyridostigmine Bromide (Mestinon)
- Neostigmine
- Cell Therapies
- CAR-T Cell Therapy
- T-Cell Receptor Therapy
- Anti-CD19 Monoclonal Antibodies (mAbs)
- Others
- Corticosteroids
- Non-Steroidal Immunosuppressants
- Purine Analogs
- Complement Inhibitors
- Global Myasthenia Gravis Treatment Type Outlook (Revenue, USD Million, 2022-2045)
- Branded
- Generics
- Global Myasthenia Gravis Treatment Distribution Channel Outlook (Revenue, USD Million, 2022-2045)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Reasons to subscribe to Global myasthenia gravis treatment market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Global myasthenia gravis treatment market databook
-
Our clientele includes a mix of myasthenia gravis treatment market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of global-level data and insights on the Global myasthenia gravis treatment market , including forecasts for subscribers. This global databook contains high-level insights into Global myasthenia gravis treatment market from 2022 to 2045, including revenue numbers, major trends, and company profiles.
Partial client list
Global myasthenia gravis treatment market size, by regions, 2022-2045 (US$M)
Top 10 countries: Myasthenia gravis treatment market size, 2021 (US$M)
Global myasthenia gravis treatment market share, by treatment type, 2021 & 2032 (%, US$M)
Myasthenia gravis treatment market: Opportunity assessment by country
Global myasthenia gravis treatment market, by region, 2024 (US$M)
Related industry reports
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
